Document text
Principal Investigator: Christopher C. Beyrer
Organization: IAS
Fiscal Year: 2023
Award: $750,000
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
IN 2021 UNAIDS estimated the HIV incidence to have been 1.5 million new infections, while the 2020 target was
set to be under 500,000 global infections for that year. At this rate, the HIV response is sharply off target to
achieve the goal of an end to the pandemic as the global public health threat by 2030.
The COVID-19 pandemic has severely affected the HIV response as it has caused consequential disruption in
the HIV response, HIV testing and prevention. Furthermore, with WHO’s declaration of Monkeypox as a public
health emergency of international concern, and this new emergence currently occurring overwhelmingly among
men who have sex with men, a community with a very high burden for HIV, there are currently three concurrent
pandemics underway challenging human health and wellbeing, health systems, and fragile public health
infrastructures worldwide. IAS 2023 must address HIV science in the context of a wider pandemic preparedness
and with a view toward the impacts of COVID-19 and Monkeypox on persons living with HIV, and on health
systems and providers. Vaccine science will be prominent, as well as antiviral agents and their interactions for
all three of these viral pandemics. Accelerate basic science and clinical science innovation in the development
and application of person-centered precision medicine for HIV treatment, reducing HIV transmission, vaccines,
pathogenesis, co-infections, and the search for a cure will feature prominently at IAS 2023.
Specific aims of IAS 2023 will be to:
1. Advance inter-disciplinary collaboration in implementation research to reduce HIV transmission and improve
treatment outcomes across all life-stages with a special focus on translating research outcomes into policy
and practice through simplified practical guidelines for low- and middle-income countries and key
populations.
2. Strengthen HIV prevention research to improve cost-effective biomedical, behavioral and structural
interventions with a special focus on understanding implementation challenges, overcoming system barriers
and replicating successes in HIV prevention practice and programs.
3. Address HIV vulnerability, determinants of HIV burdens and poor clinical outcomes among key and
marginalized populations, including interventions to reduce stigma and discrimination and improve access
and uptake of ART for prevention and treatment with a special focus on First Nations and Indigenous
communities and on person-centered approaches.
4. Re-engage and reenergize community, clinical, social and political efforts to address unmet HIV needs and
strengthen HIV policy in the Asia-Pacific region in the COVID-19 era, paying special attention to the needs
of marginalized First Nations and Indigenous communities.
The scientific program will be structured along five scientific tracks: basic science; clinical science; epidemiology
& prevention science; social and behavioural sciences; implementation science, economics, systems and
synergies. Topics to be addressed in each thematic area are described below. The scientific program is
developed by a multi-disciplinary international Organizing Committee whose members are selected on the bases
of scientific, policy and implementation expertise, meaningful engagement and representation of key and
affected populations, of civil society and / or young people and geographic and gender diversity as key
competencies and attributes ensuring diversity at all levels. Cross-cutting aspects will be highlighted in plenary
talks that also connect the science with community and leadership perspectives. Additionally, bridging sessions
are designed to cut across the different thematic areas to provide opportunities for multi-disciplinary, multi-
perspective dialogues, often using interactive formats.
Building on the success of the 24th International AIDS Conference - AIDS 2022 in hybrid format, IAS 2023 will
be held in-person and virtually, providing many opportunities for discussions, debates and interconnection
between the in-person and virtual speakers and audiences. Expected attendance is 6,000 HIV scientists,
clinicians, policy makers, and program implementers as well as civil society, community and private sector
representatives (4,500 in person and 1,500 online). IAS 2023 will provide scholarships to ensure the full
participation of researchers, community activists and civil society representatives, especially those from
resource-limited settings and underrepresented communities. Guided by best practices, the hybrid format will
maximize inclusive conference experiences for all stakeholders at all levels.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS><AIDS Virus><AIDS prevention><AIDS test><AIDS/HIV test><Acceleration><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Acquired Immunologic Deficiency Syndrome><Address><Affect><Antibody Response><Antiviral Agents><Antiviral Drugs><Antivirals><Approaches to prevention><Area><Asia><Attention><Australia><Basic Research><Basic Science><Behavioral><Behavioral Sciences><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 affected><COVID-19 consequence><COVID-19 crisis><COVID-19 effect><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 impact><COVID-19 impacted><COVID-19 pandemic><COVID-19 pandemic affected><COVID-19 pandemic consequence><COVID-19 pandemic effects><COVID-19 pandemic impact><COVID-19 pandemic impacted><COVID-19 public health crisis><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Caring><Clinic><Clinical><Clinical Sciences><CoV-2><CoV2><Cognitive Discrimination><Communities><Competence><Complex><Consensus><Country><Couples><DNA Therapy><Development><Discrimination><Disease remission><Drugs><Economics><Emergency response><Ensure><Epidemic><Epidemiology><Formulation><Fostering><Gene Transfer Clinical><Genetic Intervention><Geography><Goals><Groups at risk><Guidelines><HIV><HIV Infections><HIV Prevention><HIV test><HIV vaccine><HIV-1 test><HIV-2 test><HIV/AIDS Vaccines><HIV/AIDS prevention><HTLV-III Infections><HTLV-III-LAV Infections><Health><Health Care Providers><Health Personnel><Health system><Healthcare Providers><Healthcare worker><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Human immunodeficiency virus test><Hybrids><Immunology><Improve Access><Incidence><Individual><Infection><Infrastructure><International><International AIDS><Intervention><Intervention Strategies><Investigators><Knowledge><LAV-HTLV-III><LMIC><Leadership><Life><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Virus><MSM><Medication><Messenger RNA><Methods><Minority><Modern Man><Monkey Pox><Monkeypox><Outcome><Outcomes Research><Participant><Pathogenesis><People at risk><Personal Satisfaction><Persons><Persons at risk><Pharmaceutic Preparations><Pharmaceutical Preparations><Policies><Policy Maker><Politics><Population><Populations at Risk><Prevention><Prevention Research><Prevention approach><Prevention program><Private Sector><Public Health><RNA vaccine><RNA-based vaccine><Remission><Research><Research Personnel><Researchers><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Rights><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scholarship><Science><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Social Sciences><Stigmatization><Structure><System><Technology><Testing><Translating><Transmission><Treatment outcome><Vaccines><Viral><Viral hepatitis><Virus-HIV><Work><Wuhan coronavirus><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><barriers to implementation><base><bases><civil society><co-infection><co-morbid><co-morbidity><coinfection><comorbidity><conference><convention><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 consequence><coronavirus disease 2019 crisis><coronavirus disease 2019 effect><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 impact><coronavirus disease 2019 pandemic><coronavirus disease 2019 pandemic consequence><coronavirus disease 2019 pandemic impact><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 impact><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><cost effective><design><designing><developmental><drug/agent><economic><effects following the COVID-19 pandemic><epidemiologic><epidemiological><exhibitions><experience><forging><gender diverse><gender diversity><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><hCoV19><health care personnel><health care worker><health provider><health workforce><healthcare personnel><hepatitis virus infection><human immunodeficiency virus vaccine><implementation barriers><implementation challenges><implementation research><implementation science><improved><indigenous community><innovate><innovation><innovative><insight><interdisciplinary collaboration><interventional strategy><low and middle-income countries><mRNA><mRNA vaccine><mRNA-based vaccine><marginalization><marginalized group><marginalized individual><marginalized people><marginalized population><medical personnel><meeting><meetings><member><men having sex with men><men who have sex with men><men who have sex with other men><mpox><multidisciplinary><nCoV2><neutralizing antibody><novel><pandemic><pandemic disease><pandemic disease preparedness><pandemic planning><pandemic preparedness><pandemic readiness><patient centered><patient oriented><person centered><posters><precision medicine><precision-based medicine><prevention practice><programs><public health emergency><response><scale up><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><sex><social><social health determinants><social stigma><stigma><success><summit><symposia><symposium><synergism><transdisciplinary collaboration><transmission process><treatment provider><uptake><vaccinology><viral pandemic><virology><virtual><well-being><wellbeing>